Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (very low certainty).
1 finding from 1 review
- HR 0.95 [0.7, 1.3]1 study · 339 participantsVery low